U.S FDA approved new drug Eucrisa that contains crisaborole as topical dosage form (ointment) for the treatment of eczema ( atopic dermatitis) in patients having age 2 years or more. Eczema. Eczema or atopic dermatitis is a common skin disorder among all populations. It is intense form of skin disorder with an inflammatory response that requires long-term management or sometimes life time management in advance stages.
Exact underlying cause of eczema is not fully understood that triggers inflammatory response. It is proposed that genetic predisposition, environmental factors and immunogenic response play key role in the parthenogenesis of eczema. Most common symptoms of eczema include dry and red scaly appearance of affected area of skin with intense itching. Scratching may cause skin thickness along with swelling that prolongs the duration of therapy.
Main mechanism of Eucrisa/crisaborole is inhibition of phosphodiesterase-4 that causes inflammation by triggering the release of certain inflammatory mediators like interleukin-12(IL-12), bradykinins, cytokinins and tumor necrosis factor (TNFα). As name indicates that it contains boron that penetrates readily and rapidly into skin is essential for its binding activity.
Eucrisa/crisaborole Side effectsAccording to clinical data provided by health authorities following side effects were documented during clinical trials
- Hypersensitivity reactions
- Burning sensation
- Sting like feeling
- Mild pain during application